Why I Take Mitopure PRO

Every cell runs a constant quality-control process on its own mitochondria. A mitochondrion that's accumulated damage — a torn membrane, a mutated stretch of its own DNA, a leaky electron transport chain that's throwing off more free radicals than it should — gets tagged for removal by a pathway built around two proteins, PINK1 and Parkin, then broken down and its components recycled. That whole tag-and-remove cycle is mitophagy. It runs continuously in a healthy young cell, keeping the average quality of a cell's mitochondrial population high even as individual units wear out.

The mechanism that seems to fail with age isn't mitochondrial function directly — it's the removal step. Damaged mitochondria linger longer than they should, and the cellular average degrades. That's a distinct problem from "not enough mitochondria" or "not enough fuel for the mitochondria I have," which is exactly why it needs its own lever rather than being solved by more of what I was already taking.

Urolithin A doesn't occur directly in any food. What pomegranates, walnuts, and certain berries actually contain are ellagitannins and ellagic acid — precursor compounds that have to be converted into urolithin A by specific gut bacteria before the body can use them. This turns out to be the single biggest reason I'm taking a purified, dosed form of the metabolite itself rather than trying to eat my way there.

Not everyone's gut microbiome can make that conversion. Researchers group people into three "urolithin metabotypes" based on what their gut bacteria are actually capable of producing from the same dietary input:

One U.S. cohort study of 100 participants found roughly a third produced essentially no urolithin A from dietary precursors at all, and another quarter were low producers — meaning well over half the group would have gotten little to no benefit from a pomegranate-based strategy, regardless of how much they ate. Supplementing directly with the finished metabolite sidesteps the entire question of which metabotype I happen to be. It's also, notably, the same logic behind the rest of my gut protocol: the bacterial species capable of this conversion overlap with the same keystone gut ecology — Akkermansia among them — that the rest of my microbiome-repair work is already trying to rebuild. Whether or not that rebuild eventually makes me an efficient endogenous producer, taking the metabolite directly removes the dependency now.

I already had two supplements aimed at mitochondrial function before adding this one. Laid side by side, the division of labor is the whole rationale:

I want to be direct about where this sits on the evidence spectrum, because it's newer and thinner than most of what's in my protocol. Here's what's actually been shown, in humans, with this specific branded ingredient — in order:

Aerobic capacity — VO2max — is the number I actually care most about tracking over the next decade, so I want to lay out exactly what the trial data does and doesn't say, rather than round it up.

In the 2022 ATLAS trial, participants at the 1,000mg dose showed a meaningful within-group increase in peak oxygen consumption and total cycling distance from baseline to the end of the four-month study — cycling distance rose about 15%, for example — and the study authors described the aerobic endurance signal as "clinically meaningful." But when that same VO2max change was compared directly against the placebo group, it did not reach statistical significance, and neither did the trial's actual pre-registered primary endpoint, peak power output. The older-adult JAMA Network Open trial the same year didn't test VO2max directly; its closest analog, the 6-minute walk distance, also fell short of significance against placebo, even though muscle endurance itself improved clearly.

So the honest read is this: urolithin A has a real, plausible mechanistic reason to help aerobic capacity — mitophagy directly affects how efficiently muscle mitochondria produce ATP under sustained effort, which is a core determinant of VO2max — and the directional signal in the one trial that measured it was positive and dose-dependent. But it has not yet been shown, in a placebo-controlled human trial, to significantly raise VO2max on its own. I'm including it in my protocol as a plausible contributor to the aerobic-capacity work I'm already doing through structured training, not as a stand-in for it. If my own VO2max trend moves meaningfully over the next few training cycles, that's useful signal — but I won't be attributing it to urolithin A alone, because my training load is changing at the same time.

Urolithin A isn't a commodity ingredient the way, say, magnesium is. It's a specific molecule that has to be produced and dosed correctly to match what was actually studied, and the branded ingredient behind essentially all of the human trial data — Mitopure, made by the Swiss biotech Amazentis — is not the same thing as generic "urolithin A" sold on the open market.

That distinction matters more than usual here: independent testing on two competing urolithin A products sold on Amazon found zero detectable urolithin A in either one, despite label claims. I'm sourcing the practitioner-channel Mitopure product — dosed at the full 1,000mg/day used in the functional-outcome trials above — rather than a lower-dose, direct-to-consumer version, specifically so the dose and the ingredient match what was actually studied, not a diluted or unverified stand-in for it.

1,000mg/day (two capsules), taken fasted first thing in the morning alongside the rest of my morning capsule stack. Unlike some of my other fat-soluble supplements, urolithin A's absorption isn't meaningfully dependent on being taken with food, so there's no reason to hold it for a later meal. It runs on its own independent evaluation cycle — it isn't stacked with any other new addition, so if something changes at the 90-day mark, I'll know what caused it.

Across the human trials above, urolithin A at doses up to 1,000mg/day has consistently been reported as safe and well-tolerated, with no serious adverse events attributed to the compound. It doesn't share metabolic pathways with anything else currently in my stack, so there's no interaction risk with the rest of my mitochondrial supports or anything else I'm taking. That safety profile is a meaningful part of why I'm willing to take an earlier-stage bet on the functional-outcome evidence: the downside risk is low even if the upside doesn't fully materialize.

There isn't a blood marker that directly measures mitophagy activity, so this isn't something I can track on a lab panel the way I can watch, say, ApoB respond to a dietary change. That's a deliberate trade-off I'm making with eyes open: I'm reassessing at 90 days on subjective signals — training recovery, endurance, how I feel coming back from hard sessions — and I'll watch for anything unexpected on my next full lab panel, but I'm not expecting or looking for a specific number to move on its own.